Technical Analysis for XLO - Xilio Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 1.20 | -6.29% | -0.08 |
XLO closed up 4.07 percent on Thursday, April 18, 2024, on 11 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 8
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | -6.29% | |
Narrow Range Bar | Range Contraction | -6.29% | |
Wide Bands | Range Expansion | -6.29% | |
MACD Bearish Signal Line Cross | Bearish | -2.48% | |
Wide Bands | Range Expansion | -2.48% | |
Wide Bands | Range Expansion | -7.73% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | -4.80% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -4.80% | |
Inside Day | Range Contraction | -4.80% | |
Wide Bands | Range Expansion | -4.80% |
Alert | Time |
---|---|
Fell Below Previous Day's Low | 19 minutes ago |
60 Minute Opening Range Breakdown | about 2 hours ago |
Down 5% | about 2 hours ago |
Down 3% | about 3 hours ago |
Down 2 % | about 4 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Tumor Cancer Immunotherapy Immunotherapies Immune Checkpoint Checkpoint Inhibitor Tumor Microenvironment
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Tumor Cancer Immunotherapy Immunotherapies Immune Checkpoint Checkpoint Inhibitor Tumor Microenvironment
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.393 |
52 Week Low | 0.49 |
Average Volume | 1,442,310 |
200-Day Moving Average | 1.57 |
50-Day Moving Average | 0.86 |
20-Day Moving Average | 1.14 |
10-Day Moving Average | 1.29 |
Average True Range | 0.18 |
RSI (14) | 57.98 |
ADX | 37.33 |
+DI | 29.55 |
-DI | 12.16 |
Chandelier Exit (Long, 3 ATRs) | 1.39 |
Chandelier Exit (Short, 3 ATRs) | 1.13 |
Upper Bollinger Bands | 1.72 |
Lower Bollinger Band | 0.57 |
Percent B (%b) | 0.62 |
BandWidth | 99.96 |
MACD Line | 0.13 |
MACD Signal Line | 0.14 |
MACD Histogram | -0.0112 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.40 | ||||
Resistance 3 (R3) | 1.39 | 1.33 | 1.38 | ||
Resistance 2 (R2) | 1.33 | 1.30 | 1.34 | 1.37 | |
Resistance 1 (R1) | 1.31 | 1.28 | 1.32 | 1.32 | 1.37 |
Pivot Point | 1.25 | 1.25 | 1.26 | 1.26 | 1.25 |
Support 1 (S1) | 1.23 | 1.22 | 1.24 | 1.24 | 1.19 |
Support 2 (S2) | 1.17 | 1.20 | 1.18 | 1.19 | |
Support 3 (S3) | 1.15 | 1.17 | 1.18 | ||
Support 4 (S4) | 1.16 |